Regentis Biomaterials Ltd. (NYSE American: RGNT) has announced plans to initiate European surgeon training activities in the third quarter of 2026, marking a key step in the commercial launch of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on training program is designed to provide orthopedic surgeons with practical experience using the company’s cell-free implant, with the first sessions expected to take place at Humanitas Research Hospital in Milan, Italy, followed by additional sessions across Europe.
According to the company, the training initiative is a critical component of its European commercialization strategy and will be supported by a network of Centers of Excellence. These centers will focus on surgeon education, clinical guidance, and knowledge sharing to expand physician familiarity with the technology. GelrinC is described as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes that increasing surgeon familiarity will support adoption as the product enters broader clinical use.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions, with an initial emphasis on orthopedic treatments. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The company estimates that GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. The European commercial launch could provide a new option for patients suffering from knee cartilage lesions, potentially impacting the orthopedic industry by offering a ready-to-use, single-step procedure that may reduce the need for more invasive surgeries.
For more information, the full press release is available at https://ibn.fm/QOWWK. Updates and news related to Regentis Biomaterials can be found in the company’s newsroom at https://ibn.fm/RGNT.
